POST STROKE BRAIN RECOVERY TARGETING BLOOD FLOW AND VESSEL HEALTH
Dr Daniel Beard,
Senior Lecturer, University of Newcastle
Group Leader, Neurovascular Research Laboratory
New South Wales, Australia &
Visiting Scientist,
University of Oxford, United Kingdom &
Founder and Chief Scientific Officer
ShearFlow
RESEARCHER PROFILE
Filmed in Newcastle, Australia | May 2026
Dr Daniel Beard is a Senior Lecturer and Group Leader of the Neurovascular Research Laboratory at the University of Newcastle, with a distinguished career in stroke research. Dr Beard completed his PhD in Human Physiology in 2015, uncovering the impact of intracranial pressure on collateral vessel failure. He has held prestigious research and teaching roles at the University of Oxford and Charité Universitätsmedizin Berlin, contributing to international collaborations on neurovascular protection. His research has been supported by competitive grants, including an NHMRC Ideas Grant, and he has received numerous awards for innovation, research excellence and teaching excellence, including:
-Winner of the Challenger Pitch Prize at the Proto Axiom Challenger Summit (2024).
-Paul Dudley White International Scholar for the highest-ranked Australian abstract at the 2022 International Stroke Conference, New Orleans.
-Recipient of the Learning Design and Teaching Innovation Teaching Excellence Award and Mid-Career Teaching Award from the University of Newcastle (2024).
His most recent work focuses on understanding and improving collateral blood flow during ischaemic stroke. Notably, his groundbreaking work on shear stress and cerebral blood flow with renowned researchers at Harvard University, resulted in a patented nanoparticle therapy that selectively boosts brain perfusion during stroke, saving brain tissue and improving patient outcomes. This work was recently published in Advanced Science: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202506276.
Dr Beard is Founder and Chief Scientific Officer of the University spinout ShearFlow that is now commercializing this technology to reach the clinic. This work aims to deliver targeted stroke therapies that could give patients a improved chance at recovery and a better quality of life.
Source: Supplied and adapted
https://orcid.org/0000-0002-3720-7588
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
Identification & characterisation of molecular drivers of therapeutic resistance
Professor Pieter Eichhorn is an internationally experienced cancer biologist and research leader whose career has been defined by high-impact contributions at the interface of functional genomics, translational oncology, and research infrastructure strategy.
He completed his PhD at the University of Newcastle upon Tyne, contributing to the cloning of the gene associated with Cornelia de Lange Syndrome, before undertaking postdoctoral training at the Netherlands Cancer Institute in the laboratory of René Bernards. There, he performed pioneering functional genetic screens that identified key regulators of oncogenesis and therapy resistance, including critical roles for the PI3K signalling pathway in resistance to targeted breast cancer therapies.
-
Dr Lisa Melton
RESEARCH IN SANFILIPPO
@ SANFILIPPO CHILDREN’S FOUNDATION
SYDNEY, NEW SOUTH WALES, AUSTRALIA
